FDA widens scope of Pfizer’s Sutent in kidney cancer
Pfizer | November 17, 2017
The US Food and Drug Administration has cleared Pfizer’s Sutent for adjuvant treatment of adults at a high risk of their kidney cancer returning after a kidney has been removed.